Analysis of cumulative probabilities shows that the efficacy of 5HT(3) antagonist prophylaxis is not maintained

被引:36
作者
deWit, R
Schmitz, PIM
Verweij, J
deBoerDennert, M
deMulder, PHM
Planting, AST
vanderBurg, MEL
Stoter, G
机构
[1] ROTTERDAM CANC INST,DANIEL DEN HOED KLIN,DEPT MED STAT,3075 EA ROTTERDAM,NETHERLANDS
[2] UNIV NIJMEGEN,ACAD HOSP,DEPT MED ONCOL,NIJMEGEN,NETHERLANDS
关键词
D O I
10.1200/JCO.1996.14.2.644
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Several investigators have reported that the efficacy of 5HT(3) receptor antagonists is maintained over repeated cycles of chemotherapy. These investigators presented conditional probabilities of protection. Because conditional analyses by definition only include patients with protection in previous cycles, the results are flattered. Patients and Methods: We applied a novel statistical approach to investigate whether the efficacy of the 5HT(3) receptor antagonist ICS 205-930 (tropiseltron) is maintained over repeated cycles of weekly high-dose cisplatin. Overall protection was determined based on cumulative probabilities with the Kaplan-Meier method. Complete protection was calculated with a three state model for transitional probabilities. Eighty-three patients were studied. Results: Over six consecutive cycles, protection against both acute and delayed emesis decreased significantly. The initial complete and overall protection rates against acute emesis of 71% and 95%, respectively, decreased to 43% and 72% in the sixth cycle of chemotherapy, Similarly, the protection rates of 31% and 68% against delayed emesis decreased to 6% and 40%, respectively. Conclusion: We conclude that overall and complete long-term protection is more accurately measured by cumulative probabilities than with a method that is based on conditional probabilities. Our statistical approach shows that the efficacy of 5HT(3) antagonists is not maintained. (C) 1996 by American Society of Clinical Oncology.
引用
收藏
页码:644 / 651
页数:8
相关论文
共 25 条
[11]  
KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P15
[12]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[13]   CONTROLLING DELAYED VOMITING - DOUBLE-BLIND, RANDOMIZED TRIAL COMPARING PLACEBO, DEXAMETHASONE ALONE, AND METOCLOPRAMIDE PLUS DEXAMETHASONE IN PATIENTS RECEIVING CISPLATIN [J].
KRIS, MG ;
GRALLA, RJ ;
TYSON, LB ;
CLARK, RA ;
CIRRINCIONE, C ;
GROSHEN, S .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) :108-114
[14]  
KRIS MG, 1992, CANCER, V70, P1012
[15]   TROPISETRON - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL AS AN ANTIEMETIC [J].
LEE, CR ;
PLOSKER, GL ;
MCTAVISH, D .
DRUGS, 1993, 46 (05) :925-943
[16]   PROGRESSIVE LOSS OF ANTIEMETIC EFFICACY DURING SUBSEQUENT COURSES OF CHEMOTHERAPY [J].
MARTIN, M ;
DIAZRUBIO, E ;
CASADO, A ;
DOMINGUEZ, S ;
SASTRE, J .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :430-432
[17]   COMPARISON OF THE 5-HYDROXYTRYPTAMINE3 (SEROTONIN) ANTAGONIST ONDANSETRON (GR-38032F) WITH HIGH-DOSE METOCLOPRAMIDE IN THE CONTROL OF CISPLATIN-INDUCED EMESIS [J].
MARTY, M ;
POUILLART, P ;
SCHOLL, S ;
DROZ, JP ;
AZAB, M ;
BRION, N ;
PUJADELAURAINE, E ;
PAULE, B ;
PAES, D ;
BONS, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (12) :816-821
[18]  
PLANTING A, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P225
[19]  
PLANTING A, 1993, P AM SOC CLIN ONCOL, V12, P353
[20]  
PLANTING A, 1993, EUR J CANCER S6, V29, pS184